Besides safety/risk, effectiveness and economic aspects, other examples of topics included were (i) approval of new antidiabetic medicine (dapagliflozin) by the US Food and Drug Administration; (ii) new routes of insulin delivery, i.e., tablet/pill and inhaler; and (iii) medication non-adherence in diabetes patients commonly related to metformin and DPP4 inhibitor use due to side-effects (diarrhoea, flatulence). This evidence concerns the gene DPP4 and diabetes mellitus.